The review, authored by Mohammad Ali Mahdiabadi, Asma Moghaddam, and Nafiseh Erfanian, synthesizes evidence that microbiome-derived tryptophan metabolites act as endogenous ligands for the aryl hydrocarbon receptor, or AhR, a transcription factor long studied as a sensor of environmental toxins but now recognized as a central regulator of intestinal homeostasis. In its resting state, AhR sits in the cytoplasm bound to a complex of chaperone proteins. When a ligand binds, the receptor moves into the nucleus, pairs with the AhR nuclear translocator, and switches on genes involved in epithelial maintenance, immune regulation, and detoxification. The gut bacteria supply a steady stream of these ligands: indole-3-aldehyde, indole-3-propionic acid, indole-3-lactic acid, and indole-3-acetic acid, all produced from tryptophan by enzymes such as tryptophanase distributed across Lactobacillus, Clostridium, Bifidobacterium, Bacteroides, and Escherichia coli species.

The foundational observation came from Zelante and colleagues in 2013, who showed that when dietary tryptophan is plentiful, gut lactobacilli shift toward tryptophan catabolism and produce indole-3-aldehyde, which drives AhR-dependent production of interleukin-22. This cytokine, secreted by innate lymphoid cells type 3 and T helper 17 cells, promotes epithelial regeneration, antimicrobial peptide output, and goblet cell function. Later work extended the template to tight junction preservation, mucus maintenance, and intestinal stem cell renewal, establishing the microbiota-tryptophan-AhR axis as a mechanistic linchpin of mucosal health.

Each major metabolite has now been dissected in preclinical colitis models. Indole-3-aldehyde, produced notably by Lactobacillus reuteri, reduces inflammatory cytokines such as interleukin-6, restores the tight junction proteins zonula occludens-1 and occludin, and improves measures of barrier integrity in dextran sulfate sodium colitis. Interestingly, two studies report different degrees of AhR dependence: one found the protection only partially dependent on the receptor, while a more recent analysis documented a strictly AhR- and AMPK-dependent mechanism, with efficacy nearly abolished by receptor inhibition. The discrepancy, the review suggests, likely reflects differences in dosing, treatment duration, and model responsiveness rather than contradictory biology, underscoring that receptor dependence is not an all-or-none property even for a single ligand.

Indole-3-propionic acid, efficiently produced by Clostridium sporogenes, restores tight junction proteins and induces interleukin-22 in ulcerative colitis models, and metabolomic studies consistently find it depleted in IBD patients in correlation with disease severity. Yet its pharmacology is complicated: recent work indicates it can also act directly on heat shock protein 70 to trigger apoptosis of inflammatory Th1 and Th17 cells, independently of AhR or the pregnane X receptor it additionally engages. Indole-3-lactic acid from Lactiplantibacillus plantarum activates both AhR and the antioxidant regulator Nrf2 while suppressing nuclear factor-kappa B, coordinating barrier protection and anti-inflammatory signaling through a single metabolite. Indole-3-acetic acid, by contrast, retains anti-inflammatory activity even when AhR is pharmacologically blocked, showing that at least some protective effects of the indole class operate through receptor-independent routes such as heme oxygenase-1 induction and free radical scavenging.

Downstream of AhR, the review maps an integrated signaling network rather than a simple linear cascade. The AhR-AMPK axis links metabolite sensing to autophagy and mitochondrial resilience in epithelial cells. AhR-Nrf2 crosstalk, though not a strictly hierarchical relationship, induces antioxidant enzymes including superoxide dismutase, catalase, and heme oxygenase-1, blunting the oxidative stress that drives NF-kappa B activation. AhR signaling also directly induces interleukin-22 transcription in immune cells and upregulates the interleukin-10 receptor on epithelia, amplifying anti-inflammatory STAT3 signaling. Finally, AhR-dependent reduction of myosin light chain phosphorylation relaxes the actomyosin cytoskeleton, easing junctional tension and lowering paracellular permeability, the hallmark of the so-called leaky gut.

The review’s most conceptually important contribution may be its insistence that this axis is bidirectional. Active inflammation induces indoleamine 2,3-dioxygenase 1, which diverts tryptophan away from microbial indole synthesis and into the host kynurenine pathway, further depleting protective AhR ligands precisely when the barrier needs them most. Dysbiosis in IBD simultaneously strips away the metabolite-producing taxa themselves, including Lactobacillus, Clostridium clusters, and Allobaculum species. The result is a self-reinforcing loop in which inflammation suppresses the very metabolites that would repair the tissue damage inflammation causes, and CARD9 deficiency, a human genetic risk factor for Crohn’s disease, has been shown to impair this axis by reducing AhR ligand-producing commensals.

Crucially, the authors caution that AhR activation is not uniformly beneficial. Microbial indoles are weak, rapidly metabolized agonists that produce the transient, low-amplitude receptor engagement compatible with tissue repair. Host-derived kynurenine metabolites, or sustained high-affinity activation by compounds such as dioxin, can drive immunosuppressive, barrier-impairing, or even pro-tumorigenic programs. Cell-type-specific transcriptional landscapes add further complexity, and in autoimmune models high-affinity ligands can promote Th17 differentiation, a potentially inflammation-amplifying outcome whose relevance for microbiota-derived indoles remains incompletely characterized. Therapeutic strategies, the review argues, must therefore be ligand-selective, replicating physiological kinetics rather than broadly amplifying AhR signaling.

On the translational front, human evidence remains supportive but limited. Multiple metabolomic cohorts have independently confirmed reduced fecal indole-3-acetate and indole-3-propionate in IBD patients, and direct tissue studies show that AhR expression is reduced in IBD mucosa while remaining functionally responsive to agonist stimulation. A randomized trial of indigo naturalis, an AhR-ligand preparation, achieved significant mucosal healing in ulcerative colitis but was halted early over pulmonary safety concerns, providing proof of concept without an approved therapy. No randomized human trial has yet tested purified indole metabolites, defined probiotic strains, or postbiotic formulations targeting this axis, and most mechanistic data derive from the acute DSS colitis model, which poorly replicates the chronic, immune-mediated pathology of human disease.

The authors propose postbiotics, standardized preparations of purified metabolites such as indole-3-aldehyde, indole-3-propionic acid, and indole-3-lactic acid, as the most practical near-term strategy, offering dose standardization, stability, and direct mechanistic targeting compared with live probiotics. Compounds such as berberine and ganoderic acid A, which enhance endogenous microbial tryptophan metabolism, represent indirect alternatives. But the review closes with measured language: targeting the microbial tryptophan-AhR axis is biologically compelling yet clinically unproven, and its translation will depend on well-designed interventional trials, standardized metabolomic methodology, careful attention to ligand selectivity, and honest reckoning with the feedback loop through which inflammation itself sabotages the repair machinery. Until those data arrive, the trillions of bacteria metabolizing a single dietary amino acid remain both the most promising and the least clinically validated allies in the fight against inflammatory bowel disease.

Subject of Research: Microbiome-derived tryptophan metabolites as ligands of the aryl hydrocarbon receptor that regulate epithelial barrier integrity in inflammatory bowel disease.

Article Title: Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease

Article References: Mahdiabadi, M. A., Moghaddam, A., & Erfanian, N. (2026). Microbiome‐Derived Tryptophan Metabolites Regulate AhR Signaling to Restore Epithelial Barrier Integrity in Inflammatory Bowel Disease. MicrobiologyOpen, 15(5), Article e70386. https://doi.org/10.1002/mbo3.70386

Image Credits: AI Generated

DOI: 10.1002/mbo3.70386

Keywords: inflammatory bowel disease, gut microbiome, tryptophan metabolism, aryl hydrocarbon receptor, indole metabolites, epithelial barrier, tight junctions, interleukin-22, postbiotics, dysbiosis, microbiome-targeted therapy, Microbiome

The consortium’s central message is that the intestinal stem cell is not a fixed identity but a flexible state dictated by its surroundings. Historically, researchers divided intestinal stem cells into two camps: actively self-renewing cells marked by the gene Lgr5, which continuously fuel the everyday turnover of the epithelium, and a facultative or ‘reserve’ population, sometimes called revival stem cells, that normally rests but springs into action after catastrophic injury. Landmark studies identified Bmi1, Hopx, and other markers for these reserve cells, and work by Tian and colleagues showed that a reserve population could render Lgr5-positive cells dispensable under certain conditions. The new Roadmap argues that neither population is intrinsically determined; rather, homeostatic and regenerative properties emerge from signals emanating from a specialized local niche, the microenvironment that cradles the stem cells and instructs their behavior.

That niche has turned out to be far more complex than early models suggested. In the small intestine, Paneth cells interdigitated among the stem cells at the crypt base supply Wnt ligands, antimicrobial peptides, and metabolic support, although studies by Kim, Escudero, and Shivdasani demonstrated that Lgr5 stem cells can function even without Paneth cells, pointing to redundant support systems. Surrounding the crypts lies a constellation of mesenchymal cell types, each with distinct jobs. PDGFRα-positive pericryptal stromal cells and GLI1-expressing cells serve as critical sources of Wnts and the Wnt-amplifying protein RSPO3, while FOXL1-positive telocytes, CD34-positive mesenchymal cells, and distinct smooth muscle layers contribute additional Wnt ligands, bone morphogenetic protein gradients, and structural organization. Graded BMP signaling within the crypt architecture, as shown by Kraiczy and colleagues, even directs the self-organization of the Wnt-secreting niche itself, revealing an intricate feedback loop between epithelium and stroma.

Beyond fibroblasts, the consortium highlights an expanding cast of niche regulators. Lymphatic vessels act as signaling hubs, with lymphangiocrine signals required for proper repair after cytotoxic injury. Enteric glial cells, macrophages, and type 3 innate lymphoid cells all modulate stem cell activity, the latter through the cytokine interleukin-22, which promotes stem-cell-mediated epithelial regeneration and protects stem cells from immune-mediated damage. Even nerves participate: adrenergic nerves regulate intestinal regeneration through IL-22 signaling from innate lymphoid cells, and nociceptive neurons have been implicated in tumor progression via a CGRP-RAMP1 axis. Mechanosensing adds another dimension, with PIEZO-dependent mechanical signals proving essential for stem cell fate decisions. The picture that emerges is of a layered, multi-tissue ecosystem in which epithelial, mesenchymal, immune, vascular, lymphatic, and neural components jointly govern when stem cells divide, differentiate, or revert to a fetal-like regenerative program.

Cellular plasticity sits at the heart of this regenerative capacity. When Lgr5-positive stem cells are ablated, a remarkable variety of differentiated and progenitor cells can dedifferentiate and rebuild the stem cell compartment. Dll1-positive secretory progenitors, enterocyte-lineage daughters, Paneth cells responding to Notch activation, enteroendocrine lineage cells, and even tuft cells, which Huang and colleagues showed act as regenerative stem cells in the human intestine, have all been documented to revert. Single-cell transcriptomics revealed a revival stem cell state marked by fetal programs, and parasitic helminths were found to induce fetal-like reversion in the niche as part of the immune response. Chromatin studies explain how this is possible: the intestinal epithelium maintains broadly permissive chromatin that allows rapid switching between lineages, while factors such as Ascl2, ATOH1 phosphorylation, and Frizzled5-controlled chromatin accessibility orchestrate the dedifferentiation process. In disease, this plasticity is a double-edged sword, since the same reserve and revival programs that heal wounds can seed radioresistant, cancer-initiating populations.

Translating this biology into therapies has been propelled by organoid technology, one of the field’s transformative breakthroughs. In 2009, Sato and colleagues showed that single Lgr5 stem cells could build crypt-villus structures in vitro without a mesenchymal niche, and Ootani’s team sustained intestinal epithelium in a Wnt-dependent stem cell culture system the same year. Human colon, adenoma, and Barrett’s epithelium organoids followed in 2011, as did the directed differentiation of human pluripotent stem cells into intestinal tissue by Spence and colleagues. The technology has since matured dramatically: scaffold-guided morphogenesis produces homeostatic mini-intestines, organoid-derived tissues have repaired damaged bowel in vivo, patient-derived jejunal mucosal grafts have been engineered from children with intestinal failure, and organ-repurposing approaches have treated short bowel syndrome in preclinical models. Human intestinal organoids transplanted into humanized mice develop immune tissue, and coordinated differentiation protocols now generate organoids with functional enteric neurons and vasculature, bringing engineered gut tissue closer to clinical reality.

The consortium also emphasizes how organoids and microfluidic gut-on-a-chip systems have become indispensable for studying host-pathogen interactions. Complex human gut microbiomes have been cultured in anaerobic intestine-on-a-chip devices, and human colon models have revealed uncoupled apical and basal cytotoxicity during early Clostridioides difficile toxin exposure. These platforms allow researchers to interrogate how pathogens reshape the stem cell compartment and how microbial metabolites, such as microbiota-derived lactate, accelerate stem-cell-mediated epithelial development. Innate immune receptors on the stem cells themselves, including Toll-like receptor 4 and NOD2, which protects LGR5-positive cells from reactive oxygen species through mitophagy, directly link microbial sensing to regenerative capacity, suggesting that microbiome manipulation could become a therapeutic lever for mucosal healing.

Pharmacological strategies form the second pillar of the therapeutic roadmap. R-spondin ligands, potent amplifiers of Wnt signaling, have been shown to induce intestinal stem cells, augment chemoradioprotection, promote colonic regeneration, and ameliorate experimental colitis, while surrogate Wnt agonists that phenocopy canonical signaling support organoid growth and show promise for FZD-specific activation of repair pathways. Glucagon-like peptide-2 agonists, already approved for short bowel syndrome, stimulate S-phase entry of Lgr5-positive stem cells and support stem cell and Paneth cell repair during graft-versus-host disease, with newer agents such as glepaglutide showing anti-inflammatory and mucosal regenerative effects. Structure-based design has even decoupled the tissue-protective functions of interleukin-22 from its pro-inflammatory actions, opening the door to safer regenerative cytokine therapies. The consortium cautions, however, that stimulating proliferation carries oncogenic risk, and that niche dysregulation is predicted to underlie compromised regeneration in conditions such as inflammatory bowel disease, where stem cells retain epigenetic memories of inflammation.

The Roadmap closes with a candid inventory of remaining knowledge gaps. Human intestinal stem cells differ from their mouse counterparts in ways that matter for therapy, and spatial atlases of the adult human intestine, single-cell maps of human development, and spatial transcriptomic surveys of regeneration are only now filling the void. Bioengineered colon organoids with in vivo-like complexity, bioprinted tissues recapitulating macro-scale self-organization, and instant collagen assembly for tissue engineering are pushing manufacturing capabilities forward, while lessons from the first pluripotent stem cell therapies entering the clinic, including stem-cell-derived islets for diabetes and retinal cells for macular degeneration, offer a template for regulatory and safety pathways. What the ISCC’s fifteen-year arc demonstrates is that the intestine, once considered too dynamic and complex to rebuild, has yielded its construction secrets to systematic, collaborative biology. The remaining challenge is engineering: assembling niche cells, immune compartments, vasculature, and nerves into transplantable tissue that can survive, integrate, and function in patients whose own guts can no longer keep pace. If the consortium’s roadmap holds, the era of stem-cell-built intestines may be closer than anyone dared predict when the effort began.

Subject of Research: Intestinal stem cell biology and stem cell-based strategies for intestinal regeneration and tissue engineering

Article Title: Building and regenerating intestines by manipulating intestinal stem cells

Article References: Building and regenerating intestines by manipulating intestinal stem cells. (n.d.). https://doi.org/10.1038/s41575-026-01242-4

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01242-4

Keywords: intestinal stem cells, stem cell niche, organoids, epithelial regeneration, Wnt signaling, R-spondin, interleukin-22, cellular plasticity, short bowel syndrome, inflammatory bowel disease, tissue engineering, Intestinal Stem Cell Consortium